Genetic Mechanisms in Epilepsy Disorders and Syndromes

Epilepsy encompasses a diverse group of neurological disorders characterised by recurrent seizures arising from abnormal neuronal excitability. Genetic factors range from single‐gene defects with large effect sizes to common variants each conferring modest risk. Rare de novo and inherited mutations in ion‐channel genes, synaptic regulators and transcription factors underlie many monogenic epilepsies, often manifesting in infancy or early childhood. At the same time, polygenic influences and copy number variants contribute to common generalised and focal syndromes, revealing pleiotropic links with neurodevelopmental and psychiatric conditions. Mechanistic studies highlight disruptions of GABAergic inhibition, glutamatergic signalling, membrane excitability and epigenetic regulation. Translational advances in genetic diagnostics have facilitated precise classification and prognostic stratification, while emerging gene‐based therapies and allele‐specific approaches hold promise for targeted interventions. Ongoing research continues to map the full spectrum of pathogenic variation, elucidate genotype–phenotype correlations and translate molecular insights into novel treatments for patients worldwide.

Research from Nature Portfolio

Recent studies have leveraged large‐scale genomic analyses to chart the landscape of epilepsy risk loci. A comprehensive survey of copy number variants in over half a million individuals identified more than twenty novel loci associated with seizure disorders. Phenome‐wide analyses linked individual variants to specific clinical features, producing detailed genotype–phenotype signatures for use in clinical practice. Separately, a genome‐wide mega‐analysis of more than 15,000 individuals with epilepsy and nearly 30,000 controls uncovered sixteen genome‐wide significant loci, implicating genes involved in ion‐channel function, transcriptional control and vitamin B₆ metabolism. Convergent evidence suggests a role for common variants in epigenetic regulation, enriching known antiepileptic drug targets and revealing both shared and subtype‐specific genetic architectures.

Genetic Mechanisms in Epilepsy Disorders and Syndromes publication trend

The graph below shows the total number of articles in genetic mechanisms in epilepsy disorders and syndromes across all publications each year (not limited to Nature Index journals).

Technical terms

Copy number variant (CNV): A deletion or duplication of a DNA segment whose change in copy number can alter gene dosage and function.

Genome‐wide association study (GWAS): Analysis of common genetic variants across the genome to identify those associated with disease risk.

Missense variant: A single‐nucleotide change that results in substitution of one amino acid for another in a protein.

Haploinsufficiency: A condition in which loss of one gene copy reduces gene product below a functional threshold, causing disease.

AAV9 vector: An adeno‐associated virus serotype used for gene delivery to the central nervous system.

Pleiotropy: The phenomenon by which a single genetic locus influences multiple, seemingly unrelated phenotypic traits.

References

1. Genome-wide identification and phenotypic characterization of seizure-associated copy number variations in 741,075 individuals. Nature Communications (2023).
2. Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nature Communications (2018).
3. Delineating clinical and developmental outcomes in STXBP1-related disorders. Brain (2023).
4. AAV9/SLC6A1 gene therapy rescues abnormal EEG patterns and cognitive behavioral deficiencies in Slc6a1-/- mice. Journal of Clinical Investigation (2024).
5. Haploinsufficiency underlies the neurodevelopmental consequences of SLC6A1 variants. American Journal of Human Genetics (2024).